QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

21,106 signal articles · 531 in last 24h · 103,813 total before filter · latest 20m ago
531last 24h
2510last 7d
477● bullish (7d)
255● bearish (7d)
197publishers
AllMacro232Earnings1482M&A143Regulatory15Product5Analyst29
✕ clear all filtersticker: BMYSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
BMY Q2 Deep Dive: Growth Portfolio and Pipeline Progress Drive Upgraded Outlook
StockStory4d agobullish
BMY Q2 Deep Dive: Growth Portfolio and Pipeline Progress Drive Upgraded Outlook

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on year to $12.97 billion. The company’s full-year revenue guidance of $49.5 billion at the midpoint came in 4.3% above analysts’ estimates. Its non-GAAP profit of $2.04 per share was 27.7% above analysts’ consensus estimates.

BMY